GlassScriptPhysician profile
Daniel B Kurbanov
NPI 1366856874
$3,767.53
in general payments reported to CMS, 2019-2025
22 companies · $48.32 in 2025
The $48.32 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $486 · 2021: $1,124 · 2022: $899 · 2023: $757 · 2024: $452 · 2025: $48.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.42 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,280.54 | 2021-2024 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $917.84 | 2020-2024 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.42 | 2020-2022 | |
| Harmony Biosciences LLC | $155.12 | 2020-2023 | Wakix |
| Amgen INC. | $147.70 | 2022-2024 | Tavneos |
| Chiesi USA, INC. | $113.50 | 2020 | |
| Electromed, INC. | $105.50 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $100.89 | 2023 | Dupixent |
| Grifols USA, LLC | $84.44 | 2021-2022 | |
| Mylan Specialty L.P. | $82.94 | 2021-2022 | |
| Advanced Respiratory, INC | $58.75 | 2020-2021 | |
| Zoll Respicardia, INC. | $48.32 | 2025 | Remede System |
| Takeda Pharmaceuticals U.S.A., INC. | $43.26 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $34.84 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $25.63 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.36 | 2023 | Xarelto |
| Baxter Healthcare | $22.03 | 2022 | |
| Arbor Pharmaceuticals, INC. | $21.90 | 2020 | |
| Inogen, INC. | $20.97 | 2024 | |
| Abbvie INC. | $18.24 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.59 | 2020 | |
| Genentech USA, INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kurbanov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.